North America Cancer Tissue Diagnostics Market

The North America cancer tissue diagnostics market is expected to reach US$ 1,587.38 Mn in 2027 from US$ 923.79 Mn in 2018. The market is estimated to grow with a CAGR of 6.5% from 2019-2027.

The growth of the market is driven by the factors such as, growing cancer prevalence in North American region and new product launches & FDA approvals. However, the market is likely to slower down its growth due to the lack of reimbursement policies for cancer diagnosis in the region.

Frequent FDA approvals and product launches fuel the growth of the market for cancer tissue diagnostics. Most of the major market players are involved in the manufacturing wide range of cancer diagnostics products that offer maximum advantages and early diagnosis. For instance, in June 2019, Agilent Technologies Inc. received the U.S. Food and Drug Administration (FDA) approval for its PD-L1 IHC 22C3 pharmDx assay. The assay is approved to aim in identifying patients with head and neck squamous cell carcinoma (HNSCC) for treatment with KEYTRUDA (pembrolizumab), anti-PD-1 therapy manufactured by Merck. Furthermore, In March 2018, Agilent Technologies Inc. launched a new color for immunohistochemistry: HRP Magenta for Dako Omnis. The latest staining characteristics of the chromogen will help it for the assessment of skin and lung tissue. Thus, the constant developments in technology in diagnostics along with, FDA approvals accelerate the market growth during the forecast period.

US is expected to lead the market in the North America region owing to increasing prevalence of cancer, improved diagnosis and treatment of the condition along with the advancements made by market players. Moreover, the country has several hospitals, super specialty hospitals which offers diagnostic and treatment services for the cardiovascular diseases. Therefore, considering the above mentioned factors the growth of the market in the country is likely to contribute largest share in the North America region during the forecast period.

North America Cancer Tissue Diagnostics Strategic Insights

Strategic insights for the North America Cancer Tissue Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Cancer Tissue Diagnostics Report Scope

North America Cancer Tissue Diagnostics Regional Insights

The geographic scope of the North America Cancer Tissue Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

NORTH AMERICA CANCER TISSUE DIAGNOSTICS – MARKET SEGMENTATION

By Test Type

• Immunohistochemical Tests
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Stomach Cancer
  • Others
• In Situ Hybridization Tests
  • Breast Cancer
  • Lung Cancer
  • Bladder Cancer
  • Others

Company Profiles

• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• Bio Rad Laboratories Inc.
• Abbott
• Enzo Life Sciences, Inc.
• Agilent Technologies, Inc.
• Cancer Genetics Inc.
• Merck KGaA (Sigma-Aldrich Co. LLC)
• Danaher Corporation
• Abcam plc